Melanocortin-1 receptor-specific cyclic peptides
Melanocortin receptor-specific cyclic peptides of the formula where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
1. A cyclic peptide having the structure
or a pharmaceutically acceptable salt thereof, wherein y is 1 or 2.
2. The cyclic peptide according to claim 1 , which is an acetate salt.
3. The cyclic peptide according to claim 1 , which is a trifluoroacetate salt.
4. A cyclic peptide which is
Ac-Nle-cyclo(Glu-His-D-Phe-Arg-Dab)-Trp-NH 2 (SEQ ID NO:5).
5. A cyclic peptide which is
Ac-Nle-cyclo(Glu-His-D-Phe-Arg-Dap)-Trp-NH 2 (SEQ ID NO:6).
6. A pharmaceutical composition comprising the cyclic peptide according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising the cyclic peptide according to claim 4 and a pharmaceutically acceptable carrier.
8. A pharmaceutical composition comprising the cyclic peptide according to claim 5 and a pharmaceutically acceptable carrier.
9. A method for treatment of a melanocortin receptor-mediated disease, indication, condition or syndrome in a human or non-human mammal, comprising the step of administering the pharmaceutical composition of claim 1 .
10. A method for treating a condition responsive to changes in melanocortin receptor function in a human or non-human mammal, comprising the step of administering the pharmaceutical composition of claim 1 .